Top stock, quality management, exciting sector and a still very low MC.....
Experienced US based leadership team in place with a proven track record of achieving FDA approvals
• Addressing growing, multi-billion dollar dermatology markets with no new products approved in last 20 years (within the acne space)
• Key products based on pharmaceutical grade synthetic cannabidiol (versus variable naturally derived cannabidiol), greatly enhances the probability of clinical development success
• Exclusive global rights to use PermetrexTM delivery technology for all drugs that treat skin diseases with potential to deliver near term revenues
• Accelerated development pathway for dermatology pharmaceuticals compared to standard development pathways, driving lower costs and a faster timeline to approval
• Strong intellectual property portfolio which includes 12 patent applications across 6 patent families, and substantial volumes of proprietary knowledge, know-how, and trade secrets
• Multiple near term potential revenue streams to complement longer term development upside
BOT Price at posting:
6.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)